LILLY DRNLILLY DRNLILLY DRN

LILLY DRN

No trades
See on Supercharts

Key facts today

Eli Lilly's weight loss drug tirzepatide got China's nod, boosting shares by 1.6% to $862.39, competing in a global market poised to hit $100 billion by 2030.
China's NMPA approved Eli Lilly's Tirzepatide (Mounjaro in the U.S.) for weight management and diabetes. Eli Lilly found bacteria and impurities in fake tirzepatide products.
HSBC raised the price target on Eli Lilly to $1,100 from $880 and maintained a Buy rating, with analysts having an average rating of outperform and price targets ranging from $540 to $1,100.
Analyze the impactAnalyze the impact
Market capitalization
‪4.48 T‬BRL
‪26.18 B‬BRL
‪170.45 B‬BRL
Beta (1Y)
−0.66

About Eli Lilly and Company

CEO
David A. Ricks
Headquarters
Indianapolis
Website
Employees (FY)
‪43 K‬
Founded
1876
ISIN
BRLILYBDR006
FIGI
BBG002QBHFC7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.